Matches in SemOpenAlex for { <https://semopenalex.org/work/W4237888974> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- W4237888974 endingPage "7013" @default.
- W4237888974 startingPage "7013" @default.
- W4237888974 abstract "7013 Background: A common perception of some oncologists is that the vast majority of their patients with metastatic disease will receive 2nd line treatment upon progression. Therefore, “saving” good treatment options for the future may be acceptable. We aimed to examine whether this perception correlates with real-life. Methods: Using an oncology electronic database, consisting of >27,000 patients treated at our institution, we selected consecutive patients with metastatic or locally advanced lung, colon, pancreatic, bile duct and gastric cancers who started standard 1st line, consisting of at least doublet therapy. We then assessed the correlation between proceeding to 2nd line therapy and demographic and clinical variables, including age, gender, initial BMI, hemoglobin, WBC, creatinine, glucose, calcium, as well as survival. Results: A total of 553 patients met the inclusion criteria. Their median age was 66 and 317 were men. Their diagnoses were colon (197), lung (129), pancreas (101), bile duct (71) and gastric (55) cancers. Only 59% received at least one course of 2nd line treatment (61.9% colon, 65.1% lung, 66.3% pancreas, 35.2% bile duct and 54.5% gastric). Probability of reaching 2nd line treatment was associated with disease site (P=0.0002) as well as with age, with patients who received 2nd line being 2.5 years younger compared to those who did not (65 vs. 67.5 years, P=0.008). No other factor, including gender, BMI or standard laboratory values at presentation could predict chances of proceeding to 2nd line, for either the whole group or by primary cancer origin. Survival of patients not starting 2nd line was also significantly shorter across all tumor types. Conclusions: These real-life data indicate that only 60% of patients starting standard doublet or triplet treatment for advanced cancers will commence 2nd line therapy; and this cannot be reliably predicted in advance using standard clinical and laboratory characteristics. Our data challenge the practice of saving good treatment options for subsequent lines, and call for the development of tools enabling prediction of response and tolerance to treatment, pursuing for better patient selection and patient-tailored therapy." @default.
- W4237888974 created "2022-05-12" @default.
- W4237888974 creator A5026232476 @default.
- W4237888974 creator A5083392542 @default.
- W4237888974 date "2020-05-20" @default.
- W4237888974 modified "2023-09-29" @default.
- W4237888974 title "Saving the best to the last: Can we wait for second-line?" @default.
- W4237888974 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.7013" @default.
- W4237888974 hasPublicationYear "2020" @default.
- W4237888974 type Work @default.
- W4237888974 citedByCount "0" @default.
- W4237888974 crossrefType "journal-article" @default.
- W4237888974 hasAuthorship W4237888974A5026232476 @default.
- W4237888974 hasAuthorship W4237888974A5083392542 @default.
- W4237888974 hasConcept C126322002 @default.
- W4237888974 hasConcept C143998085 @default.
- W4237888974 hasConcept C2777714996 @default.
- W4237888974 hasConcept C2778764654 @default.
- W4237888974 hasConcept C2779777945 @default.
- W4237888974 hasConcept C2780306776 @default.
- W4237888974 hasConcept C71924100 @default.
- W4237888974 hasConcept C90924648 @default.
- W4237888974 hasConceptScore W4237888974C126322002 @default.
- W4237888974 hasConceptScore W4237888974C143998085 @default.
- W4237888974 hasConceptScore W4237888974C2777714996 @default.
- W4237888974 hasConceptScore W4237888974C2778764654 @default.
- W4237888974 hasConceptScore W4237888974C2779777945 @default.
- W4237888974 hasConceptScore W4237888974C2780306776 @default.
- W4237888974 hasConceptScore W4237888974C71924100 @default.
- W4237888974 hasConceptScore W4237888974C90924648 @default.
- W4237888974 hasIssue "15_suppl" @default.
- W4237888974 hasLocation W42378889741 @default.
- W4237888974 hasOpenAccess W4237888974 @default.
- W4237888974 hasPrimaryLocation W42378889741 @default.
- W4237888974 hasRelatedWork W12280632 @default.
- W4237888974 hasRelatedWork W1367695 @default.
- W4237888974 hasRelatedWork W13695452 @default.
- W4237888974 hasRelatedWork W15154808 @default.
- W4237888974 hasRelatedWork W16969989 @default.
- W4237888974 hasRelatedWork W20029413 @default.
- W4237888974 hasRelatedWork W2592423 @default.
- W4237888974 hasRelatedWork W4670549 @default.
- W4237888974 hasRelatedWork W6333551 @default.
- W4237888974 hasRelatedWork W7816296 @default.
- W4237888974 hasVolume "38" @default.
- W4237888974 isParatext "false" @default.
- W4237888974 isRetracted "false" @default.
- W4237888974 workType "article" @default.